SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) — via IBN — TechForce Robotics, Inc. (“TechForce”), a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), today announces the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics, Inc. (OTCQB: OTLC), marked by the deployment of PUR-E, TechForce’s autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. The deployment is intended to support the evaluation of robotics and automation opportunities within sterile manufacturing and regulated operational environments.
The Phase 2 deployment follows the completion of Phase 1 objectives, which focused on materials logistics and internal transport operations using TechForce’s LIM-E autonomous GMP support robot. Phase 2 expands the initiative into OEB-5 clean room and sterile injectable manufacturing operations within the SAPU Bio cGMP environment.
PUR-E is designed to support designated clean room operations through autonomous transport, shelving-based supply movement, operational observation activities, and routine support tasks. TechForce and Oncotelic are utilizing the system to evaluate automation opportunities across sterile manufacturing operations and associated cGMP workflows.
Within SAPU Bio’s OEB-5 sterile injectable cGMP facility, PUR-E joins LIM-E as part of the ongoing robotics and automation initiative, supporting sterile manufacturing workflows and the evaluation of future electronic batch record (EBR) opportunities within the regulated environment.
The deployment is part of an ongoing joint development initiative focused on robotics, automation, and AI-driven operational technologies for high-containment pharmaceutical manufacturing environments.
TechForce Commentary
“Phase 2 represents an important step forward in our pharmaceutical automation initiative as we continue exploring how autonomous robotics can support clean room operations,” said Ried Floco, President and Director of TechForce Robotics.
“With the expansion of our work at SAPU Bio, we are continuing to advance applications for robotics within regulated laboratory environments. Our objective is to continue to identify, adapt and implement robotic technologies that streamline and support clean room personnel and operational processes across scientific, manufacturing, and quality-related functions.”
Oncotelic Therapeutics Commentary
“PUR-E joining LIM-E inside SAPU Bio’s OEB-5 sterile injectable cGMP facility is a meaningful step in advancing the evaluation of robotics, automation, and AI-driven technologies, including our PDAOAI platform, within high-containment pharmaceutical manufacturing environments,” said Saran Saund, Chief Business Officer and Head of AI of Oncotelic Therapeutics.
Continued Development of the TechForce Pharmaceutical Automation Platform
TechForce and Oncotelic expect to continue exploring additional automation opportunities under their ongoing joint development collaboration. TechForce believes pharmaceutical manufacturing, biotechnology, clean room operations, healthcare infrastructure, and life sciences environments may represent future opportunities for robotics and automation technologies.
PUR-E is part of TechForce Robotics’ Robotics-as-a-Service Provider (RaaSP) platform, which delivers autonomous robotics solutions through a subscription-based operational model that includes deployment, maintenance, support, software updates, training, and ongoing system management.
Available features, integrations, deployment configurations, and operational capabilities may vary depending on customer requirements, regulatory considerations, and operating environments.
About Oncotelic Therapeutics, Inc. (OTCQB: OTLC)
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the Company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.
Oncotelic also develops PDAOAI, its proprietary technology platform for drug discovery and automation-related initiatives. Through Oncotelic’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI supports the companies’ ongoing joint development activities related to automation initiatives within high-containment GMP manufacturing environments.
For more information about Oncotelic Therapeutics, visit www.oncotelic.com.
About Nightfood Holdings, Inc. (OTCQB: NGTF)
Nightfood Holdings, Inc. (dba TechForce Robotics) is focused on the development, integration, and deployment of autonomous robotics and automation solutions across multiple commercial industries. Through its TechForce Robotics platform, the Company develops and deploys autonomous robotic systems designed to improve operational efficiency, workflow consistency, and scalability across hospitality, commercial, laboratory, and emerging enterprise automation environments.
For more information, visit www.nightfoodholdings.com.
About TechForce Robotics, Inc.
TechForce Robotics, Inc., a subsidiary of Nightfood Holdings, Inc., develops and deploys autonomous robotic systems that support operational workflows across commercial, laboratory, hospitality, and pharmaceutical environments. Through its Robotics-as-a-Service Provider (RaaSP) model, the Company delivers robotics solutions through a subscription-based service that includes deployment, maintenance, support, software updates, training, and ongoing system management.
For more information, visit www.techforcerobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed acquisition of Jiun Jiang Enterprise Co., Ltd., the anticipated benefits of the transaction, future growth opportunities, projected revenue and profitability objectives, the valuation and earnout framework, manufacturing expansion plans, AI infrastructure and semiconductor industry trends, potential future acquisitions, the Company’s anticipated uplisting to a national securities exchange, and other future events and developments.
These forward-looking statements are based on current expectations, estimates, projections, beliefs, and assumptions of management and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Forward-looking statements are often identified by words and phrases such as “expects,” “anticipates,” “plans,” “projects,” “estimates,” “intends,” “believes,” “targets,” “may,” “could,” “would,” “will,” “should,” “potential,” “continue,” or similar expressions.
Among the factors that could cause actual results to differ materially are the parties’ ability to negotiate and execute definitive agreements, complete satisfactory due diligence, obtain required approvals, secure financing, achieve projected revenue and profitability objectives, successfully expand manufacturing operations, capitalize on anticipated market opportunities, complete a successful uplisting to a national securities exchange, and other risks and uncertainties described from time to time in the Company’s filings with the Securities and Exchange Commission.
Forward-looking statements contained in this press release speak only as of the date made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
Investor Relations & Media Relations & Corporate Communications Contacts
Investor Relations
[email protected]
Media Relations
[email protected]
Corporate Communications
[email protected]
IBN | Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000